Maharashtra FDA suspends Cipla’s Pune warehouse licences over misbranding
- Maharashtra Food and Drug Administration FDA suspended Cipla's Pune warehouse licences on 1 October.
- The action followed misbranding of 'Reactin Plus', a Schedule-H drug with illegal over-the-counter claims.
- Inspectors found medicine boxes dumped with dust, and discrepancies between stock and computer records.
- FDA Commissioner Tukaram Mundhe said the order followed Bombay High Court directions and natural justice.
Source: ndtv.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
